申请人:Fujisawa Pharmaceutical Company, Ltd.
公开号:US04349552A1
公开(公告)日:1982-09-14
A compound of the formula: ##STR1## wherein R is a bridged alicyclic group selected from the group consisting of norbornyl, norbornenyl, bicyclo[2,2,2]-heptyl and adamantyl optionally substituted by at least one substituent selected from the group consisting of lower alkyl, carboxy, lower alkoxycarbonyl, alkylidenedioxy, N,N-di(lower)alkylcarbamoyl, amino, loweralkoxycarbonylamino and halogen. The present compound is useful in the therapeutic treatment of cancer in human beings and animals.
分子式为:##STR1## 其中R是从诺博烯基,诺博烯基,双环[2,2,2]-庚烷基和金刚烷基中选择的桥式脂环基,可以选择性地被至少一种取代基所取代,所述取代基选择自下列群体:低碳基,羧基,低碳基氧羰基,烷基二氧基,N,N-二(低)烷基氨基甲酰基,氨基,低碳基氧羰基氨基和卤素。该化合物在治疗人类和动物的癌症中有用。